RxDoctor Payments Data

Marilyn Mayer, MD

Internal Medicine · Cypress, TXNPI 1205818853

Payments from drug & device makers

$4,501in general payments, 2019–2025

Across 23 payments — averaging $195.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$4K
  • Lilly USA, LLC$73
  • Optinose US, Inc.$58
  • GSK$38
  • Medtronic$34
  • Exact Sciences$32
  • plus $104 from 5 others

What the payments were for

  • Consulting fees$3,57579%
  • Travel & lodging$44410%
  • Food & beverage$48211%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,501 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$119,532
Medicare patients
253
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$123,489
JulucaDolutegravir/Rilpivirine12$41,469
OzempicSemaglutide33$30,818
TrulicityDulaglutide25$25,119
XareltoRivaroxaban31$21,438
EliquisApixaban30$20,497
VascepaIcosapent Ethyl14$9,733
JardianceEmpagliflozin11$7,560
InvokanaCanagliflozin12$5,607
SynthroidLevothyroxine Sodium84$5,515
Levothyroxine Sodium291$3,454
PaxlovidNirmatrelvir/Ritonavir18$2,808
Atorvastatin Calcium241$2,660
Venlafaxine Hcl ErVenlafaxine Hcl25$2,611
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$73$148,608122 claims
Novo NordiskOzempic$21$30,81833 claims
Boehringer IngelheimJardiance$20$7,56011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →